Iimura Yohei, Iihara Hirotoshi, Saito Yoshitaka, Nomura Hisanaga, Iwamoto Takuya, Kotera Mayumi, Tsuchiya Yusuke, Sumiya Tatsuya, Kono Mariko, Hirate Daisuke, Kurokawa Tomohiro, Hayashi Toshinobu, Hashimoto Hironobu, Higuchi Junichi, Urakawa Ryuta, Saotome Hiroyuki, Kuroda Seiichiro
Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1Minato-Ku, Shirokanedai, Tokyo, 108-8639, Japan.
Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
Int J Clin Oncol. 2025 Sep 1. doi: 10.1007/s10147-025-02868-1.
Epidermal growth factor receptor antibodies and tyrosine kinase inhibitors cause various skin toxicities. Acneiform rash, paronychia, and pruritus are the major side effects, and their incidence is high, especially in Asian patients. These skin disorders greatly reduce the patients' quality of life and can affect treatment intensity. As the incidence and severity of these skin toxicities correlate with treatment effects, adequate management during the treatment period is essential. Guidelines and treatment recommendations exist for epidermal growth factor receptor inhibitor-related skin toxicities. However, there have been no previous reviews of studies on Asian patients. In this review, we discuss the possible preventive and therapeutic recommendations for Asian patients. We derived recommendations based on evidence from Asian patients. This review will contribute to the management of these toxicities in Asian populations.
表皮生长因子受体抗体和酪氨酸激酶抑制剂会引发各种皮肤毒性反应。痤疮样皮疹、甲沟炎和瘙痒是主要的副作用,其发生率很高,尤其是在亚洲患者中。这些皮肤疾病极大地降低了患者的生活质量,并可能影响治疗强度。由于这些皮肤毒性的发生率和严重程度与治疗效果相关,因此在治疗期间进行适当管理至关重要。目前存在关于表皮生长因子受体抑制剂相关皮肤毒性的指南和治疗建议。然而,此前尚无针对亚洲患者研究的综述。在本综述中,我们讨论了针对亚洲患者可能的预防和治疗建议。我们基于来自亚洲患者的证据得出了这些建议。本综述将有助于亚洲人群中这些毒性反应的管理。